moderate to severe atopic dermatitis
Conditions
Interventions
control group:Dopliuzumab injection (Manufacturer: Sanofi-aventis groupe, approval number: Import Drug Registration number S20200017, specification: 300mg: 2ml/ branch), subcutaneous injection, the fi
treatment group:On the basis of the control group, TCM acupuncture treatment (including acupuncture and fine medicine moxibustion burning moxibustion) was added.
Sponsors
Chongqing Traditional Chinese Medicine Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for AD. 2. SCORAD score was used to evaluate the severity of the disease, moderate AD was defined as 25 ~ 50 points, severe AD was defined as > 50 points. 3. Voluntarily participate in the study and sign the informed consent. 4. The age range is 18 to 75 years old.
Exclusion criteria
Exclusion criteria: 1. There is obvious rupture, erosion, exudation and infection in local skin lesions. 2. Patients with other pruritus diseases. 3. Systemic use of glucocorticoids, immunosuppressants, and JKA inhibitors within the past 2 weeks. 4. Pregnant or lactating women. 5. there are moxibustion and acupuncture treatment contraindications. 6. accompanied by serious cardiovascular and cerebrovascular, liver, kidney, hematopoietic system and other primary diseases, as well as bleeding tendencies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| NRS score; | — |
Secondary
| Measure | Time frame |
|---|---|
| EASI score ;DLQI score ;SCORAD score ;eosinophil count;Serum total IgE level;Th1/Th2/Th17/Th22;clinical efficacy; | — |
Countries
China
Contacts
Public ContactQi Song
Chongqing Traditional Chinese Medicine Hospital
Outcome results
None listed